Invivyd, the small biotech company building an injectable, low-dose monoclonal antibody meant to protect against Covid-19 infection like a vaccine, but without the real or perceived limits of vaccines, has new data from a late-stage trial. The Phase 3 study, called LIBERTY, tested its candidate VYD2311 against Comirnaty, the established mRNA-based Covid vaccine sold by Pfizer. The results were posted on Tuesday.
Side Effects Head to Head
The study looked at how the two treatments landed in the body. After six days, 57% of participants who got VYD2311 injected into the muscle of their upper arm reported headaches, chills, fatigue or pain at the injection site — the typical side effects tied to vaccinations. In the Comirnaty arm of the study, 91% of participants reported the same side effects.
The difference was statistically significant. The same study also found VYD2311 was better tolerated at 56 days, and could be combined safely with Comirnaty.
The numbers paint a clear picture: fewer people felt bad after the antibody shot than after the vaccine.
What the Data Means
This kind of result matters because the public has concerns about vaccines. Some people avoid them out of fear, while others want a simpler path to protection. An antibody that works through injection but avoids the side effects of vaccination could fill that gap.
The LIBERTY data suggest VYD2311 can offer that alternative. The tolerability figures — 57% versus 91% — show the antibody causes far fewer side effects than the vaccine it was tested against.
The combination finding is worth noting too. The study showed VYD2311 could be given alongside Comirnaty without trouble. That means the two treatments can sit together in a person’s medical record without raising concern.
What Comes Next
The data is promising, but it is not a green light. There is an FDA hurdle ahead.
Before any regulator weighs in, Invivyd will need to build on this proof of concept. The company will likely look at longer-term safety and efficacy data. Those studies will help shape how the product is positioned in the market.
Why This Matters Now
Covid-19 remains a persistent threat, and the search for ways to fight it continues. Antibodies like VYD2311 offer a different angle — protection that acts like a vaccine but avoids the side effects that keep some people away from shots.
The LIBERTY results show that angle can work. The question now is whether regulators agree, and whether Invivyd can move fast enough to make the antibody widely available.
The company has shown the science works. The next step is proving it meets the standards set by regulators.
Key facts box:
1. Study: LIBERTY, a Phase 3 trial comparing VYD2311 to Comirnaty
2. Participants reporting side effects after six days: 57% in the VYD2311 arm, 91% in the Comirnaty arm
3. Difference: Statistically significant
4. Combination: VYD2311 can be used safely with Comirnaty
5. Timeline: Data posted on Tuesday
The takeaway is simple: Invivyd has a working candidate that beats a leading vaccine on side effects.
See the a run of 36 images at STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.